Lichen Planus Market is segmented By Type (Cutaneous Lichen Planus, Oral Lichen Planus, Genital Lichen Planus, Lichen Planopilaris, Others (e.g. Esoph....
Market Size in USD
CAGR7.6%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 7.6% |
Market Concentration | High |
Major Players | AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly and Company |
The Global Lichen Planus Market is estimated to be valued at USD 150.1 million in 2024 and is expected to reach USD 251.2 million by 2031, growing at a compound annual growth rate (CAGR) of 7.6% from 2024 to 2031. The prevalence of lichen planus is increasing globally which is driving the need for effective treatment options. Biologics and newer therapeutic approaches are being evaluated which can potentially address unmet needs and help more patients achieve remission.
The market is witnessing positive trends with growing awareness about the condition and its treatment. Advancements in therapeutics with more targeted drugs in the pipeline are likely to push the market growth during the forecast period. Moreover, rising healthcare spending in developing countries will also create new opportunities. However, high treatment cost and lack of drugs specifically approved for lichen planus may restrain the market to a certain extent over the coming years.